Why the study?
Does statin therapy in the perioperative period reduce cardiovascular adverse events and 30-day all-cause mortality in patients undergoing intermediate-risk noncardiac, nonvascular surgery?
Does statin therapy in the perioperative period reduce cardiovascular adverse events and 30-day all-cause mortality in patients undergoing intermediate-risk noncardiac, nonvascular surgery?
Perioperative statin use may reduce cardiovascular events and 30-day mortality in patients undergoing intermediate-risk noncardiac, nonvascular surgery.
No takes yet. Share an insight, caveat, or question.
May support perioperative statin consideration in intermediate-risk noncardiac surgery; leaves open confirmation by randomized trials.
Raju et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: